Abbott Laboratories (SWX:ABT)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 181.14B |
| Revenue (ttm) | 34.28B |
| Net Income (ttm) | 11.08B |
| Shares Out | n/a |
| EPS (ttm) | 6.34 |
| PE Ratio | 16.35 |
| Forward PE | 23.77 |
| Dividend | 1.96 (1.93%) |
| Ex-Dividend Date | Jul 15, 2025 |
| Volume | 35 |
| Average Volume | 2 |
| Open | 102.00 |
| Previous Close | 104.00 |
| Day's Range | 102.00 - 102.00 |
| 52-Week Range | 92.00 - 106.00 |
| Beta | 0.68 |
| RSI | 1.21 |
| Earnings Date | Jul 16, 2025 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
Chris Blumas' Past Picks: Brookfield Corp, Abbott Labs & Great-West Lifeco
Chris Blumas, Portfolio Manager at Raymond James Investment Counsel, discusses his past stock picks and how they're doing in the market today.
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $6K Worth of Abbott Laboratories Stock
A August filing shows that Representative Josh Gottheimer reported a sale in Abbott Laboratories (NYSE: ABT), valued between $6,006 and $90,000. The transaction date is listed as July 18, 2025, with ...
Abbott India's profit climbs on healthy pharmaceutical demand
Drugmaker Abbott India reported an 11.5% rise in first-quarter profit on Tuesday, driven by healthy sales in its mainstay pharmaceuticals segment.
Abbott Laboratories (ABT) Faces Stock Dip Despite Positive YTD Performance
Abbott Laboratories (ABT) Faces Stock Dip Despite Positive YTD Performance
Abbott Laboratories poised to end in red after six-session rally
Abbott Laboratories Q2 Earnings: Dividends Don't Lie
Gauzy Ltd. Announces Board of Directors Changes Following Annual Meeting
Gauzy Pleased to Announce Alejandro Weinstein, Former Director in Gauzy, Elected to Board; A Long-Time Investor and Shareholder Engaged with the Company Since 2016 Gauzy Adopts Leaner Board to Reduce ...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Paul MacDonald's Top Picks: Stryker, Abbott Labs & Elevance Health
Paul MacDonald, Chief Investment Officer & Portfolio Manager at Harvest Portfolios Group, shares his top stock picks to watch in the market.
Best Dividend Aristocrats For August 2025
Dividend Aristocrats are outperforming SPY in July but still trail year-to-date; select Aristocrats delivered double-digit gains and strong dividend growth. 47 of 69 Aristocrats raised dividends in 20...
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...
Best Dividend Kings: July 2025
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a...
Notable healthcare headlines for the week: Trump’s tariff threats, J&J, Abbott Laboratories and Sarepta in focus
Looking Into Abbott Laboratories's Recent Short Interest
Abbott Laboratories's (NYSE: ABT) short percent of float has fallen 5.83% since its last report. The company recently reported that it has 19.43 million shares sold short , which is 1.13% of all regu...
Analysts defend Abbott Labs' stock after Thursday's 'too punitive' sell-off
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
tech giants stumble as Tesla accelerates: Unpacking today's mixed market signals
📉 Technology Sector: Tech Giants Navigate Turbulence Today, the technology sector is showing signs of strain, with key players like Microsoft (MSFT) edging down by 0.17% and Oracle (ORCL) slipping by...
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
Abbott Laboratories (NYSE: ABT) reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year . The company reported ...
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.
Abbott Laboratories: What's Behind The Q2 Earnings Slump?
Microsoft To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Jefferies...
Abbott CEO Robert Ford goes one-on-one with Jim Cramer
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Didn't see the recovery in China we were expecting, says Abbott Labs CEO on lowering guidance
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction'
Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer.
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executi...